Comparative Pharmacology
Head-to-head clinical analysis: FERROUS CITRATE FE 59 versus SODIUM ROSE BENGAL I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERROUS CITRATE FE 59 versus SODIUM ROSE BENGAL I 131.
FERROUS CITRATE FE 59 vs SODIUM ROSE BENGAL I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferrous citrate Fe 59 is a radioactive isotope of iron used for diagnostic purposes. It is incorporated into hemoglobin in red blood cells, allowing visualization of erythropoiesis and imaging of the reticuloendothelial system.
Sodium rose bengal I 131 is a radioactive diagnostic agent that is taken up by hepatocytes and excreted into the bile, allowing imaging of the hepatobiliary system. The radioactive iodine (I-131) emits gamma rays, which can be detected externally to assess liver and gallbladder function.
Ferrous citrate Fe 59 is a radioactive diagnostic tracer, not a therapeutic iron supplement. Typical adult dose: 2-10 µCi (0.074-0.37 MBq) intravenously as a single dose for iron absorption or red cell utilization studies.
5-50 µCi (0.185-1.85 MBq) intravenous bolus for hepatic function imaging. For functional imaging of hepatobiliary system, typical dose: 150-300 µCi (5.55-11.1 MBq) IV.
None Documented
None Documented
Terminal elimination half-life of Fe-59 from plasma is approximately 1.5-2 hours for free iron, but for total body iron, it is about 5-6 hours initially, followed by a slow phase of 6-10 days due to redistribution to storage sites. Clinically, the long half-life allows imaging of erythropoiesis over days.
Terminal elimination half-life is approximately 3-7 days, reflecting slow clearance from the liver and bile.
Fe-59 is primarily excreted via feces (80-90%) as unabsorbed iron, with minor renal excretion (<5%) and negligible biliary elimination. Absorbed iron is incorporated into hemoglobin and red blood cells, with loss via desquamation (~1 mg/day) not reflected in excretion fractions.
Primarily hepatic excretion into bile (90-95%), with minimal renal excretion (5-10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical